These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 23140647

  • 1. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [Abstract] [Full Text] [Related]

  • 2. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [Abstract] [Full Text] [Related]

  • 3. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI.
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [Abstract] [Full Text] [Related]

  • 4. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [Abstract] [Full Text] [Related]

  • 6. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [Abstract] [Full Text] [Related]

  • 7. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL.
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [Abstract] [Full Text] [Related]

  • 8. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI, Fava M.
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [Abstract] [Full Text] [Related]

  • 9. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E, Fava M, Papakostas GI.
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [Abstract] [Full Text] [Related]

  • 10. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
    Papakostas GI, Martinson MA, Fava M, Iovieno N.
    J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
    [Abstract] [Full Text] [Related]

  • 11. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
    Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctôt KL, Grysman NH.
    J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
    [Abstract] [Full Text] [Related]

  • 12. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials.
    Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI.
    Int Clin Psychopharmacol; 2011 Mar; 26(2):69-74. PubMed ID: 20962663
    [Abstract] [Full Text] [Related]

  • 13. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P, Ten Berg MJ, Hemels ME, Einarson TR.
    Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
    [Abstract] [Full Text] [Related]

  • 14. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.
    Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI.
    J Clin Psychopharmacol; 2011 Oct; 31(5):582-6. PubMed ID: 21869696
    [Abstract] [Full Text] [Related]

  • 15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA.
    Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
    [Abstract] [Full Text] [Related]

  • 17. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of randomized, double-blind, and sham-controlled trials.
    Berlim MT, Van den Eynde F, Daskalakis ZJ.
    J Clin Psychiatry; 2013 Feb; 74(2):e122-9. PubMed ID: 23473357
    [Abstract] [Full Text] [Related]

  • 18. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME.
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [Abstract] [Full Text] [Related]

  • 19. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.
    Tedeschini E, Fava M, Goodness TM, Papakostas GI.
    Eur Neuropsychopharmacol; 2010 Aug; 20(8):562-7. PubMed ID: 20219330
    [Abstract] [Full Text] [Related]

  • 20. Can people with nonsevere major depression benefit from antidepressant medication?
    Stewart JA, Deliyannides DA, Hellerstein DJ, McGrath PJ, Stewart JW.
    J Clin Psychiatry; 2012 Apr; 73(4):518-25. PubMed ID: 22226407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.